Advanced Techniques for Optimizing Returns through Copy Trading Algorithms 
Economic Indicators from Auction Trends: What Car Auctions Reveal About Consumer Confidence 
Elon Musk Tells Users to ‘Stop Using Hashtags’ on X as Platform Moves Away From Trends 
Honda and Nissan Ready to Kick Off Integration Talks to Counter Tesla and Chinese Auto Giants 
OpenAI Heats Up AI Race with o3 Models Aiming to Outperform Google’s Gemini in Complex Problem Solving 
Starbucks Union Strike Expands Nationwide as Baristas Demand Higher Wages, Better Schedules, and Fair Staffing 
The Crypto Market is Thrown into Chaos as XRP Plummets 12% & $1 Trillion is Wiped Out 
Elon Musk Sparks Outrage Claiming 'Newsrooms Illegal for Republicans' in Wake of Shocking Journalist Data 
Dr. Joseph Mercola Debunks Common Weightlifting Myths: What You Really Need to Know for Effective Strength Training 
BC.GAME Enters Online Poker Market with BCPoker Launch Featuring Three Classic Variants 
Apple Launches Limited-Time Apple Card Sign-Up Offers: Earn Up to $300 Daily Cash Rewards 
Are we becoming too close to AI? 
Donald Trump to Allegedly ‘Waive Apple’s China Tariffs’ as He Aims to Stop Samsung From Dominating Global Market 
Effective Crisis Management for iGaming Brands 
How to use an AI art detector 
NEW YORK, Aug. 24, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Lipocine Inc. (“Lipocine” or “the Company”) (NASDAQ:LPCN) between June 30, 2015 and June 28, 2016. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the District of New Jersey. To get more information go to:
http://www.zlk.com/pslra/lipocine-inc
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period, defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) Lipocine’s filing of its New Drug Application for LPCN 1021, Lipocine’s lead product candidate, contained deficiencies; and (2) as a result, defendant’s statements about Lipocine’s business and operations were false and misleading and/or lacked a reasonable basis.
On June 29, 2016, Lipocine announced that the U.S. Food and Drug Administration had issued a Complete Response Letter regarding the Company’s New Drug Application for LPCN 1021. According to the Complete Response Letter, the FDA has identified deficiencies related to the dosing algorithm for the label and concluded the application was not ready for approval in its present form.
If you suffered a loss in Lipocine you have until August 30, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
